Posts

Myovant Sciences agreed to be acquired by Sumitovant Biopharma for $2.9 billion – three weeks after turning down a previous offer.

Myovant Sciences announced Sunday it formed a special committee of independent directors to assess Sumitovant Biopharma’s offer to acquire the company, and ultimately, turned the offer down.

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2022 Prix Galien USA Award nominees for “Best Biotechnology Product,” “Best Pharmaceutical Agent,” and “Best Medical Technology.” Winners will be announced during the Prix Galien USA Awards Ceremony on October 27, 2022, at the American Museum of Natural History in New York City.